Neuregulin-1 Promotes Myocardial Angiogenesis in the Rat Model of Diabetic Cardiomyopathy

Cell Physiol Biochem. 2018;46(6):2325-2334. doi: 10.1159/000489622. Epub 2018 May 4.

Abstract

Background/aims: Microvascular insufficiency takes a critical role in the development of diabetic cardiomyopathy (DCM). So this study was designed to investigate the effects of Neuregulin-1 (NRG-1) treatment on myocardial angiogenesis and the changes of VEGF/Flk1 and Ang-1/Tie-2 signaling in the rat model of DCM.

Methods: Diabetic rats were induced by a single intraperitoneal injection of Streptozotocin. 12 weeks after the diabetes induction, the rats with NRG-1 treatment were treated with tail vein injection of NRG-1 at the dose of 10µg/kg/d for consecutive 10 days. Cardiac function was assessed using catheter MPA cardiac function analysis system. Myocardial blood flow (MBF) was assessed with stable-isotope labeled microspheres. Capillary density was measured by CD31 immunohistochemistry. The protein expression and receptors phosphorylation were assessed using western blot.

Results: Left ventricular function, capillary density and MBF were significantly reduced in DCM group when compared with those in the control group (P< 0.01, P< 0.01 and P< 0.05 respectively). Left ventricular function and capillary density were significantly increased in NRG-1 treatment group when compared with those in the DCM group (P< 0.05 and P< 0.05 respectively). The expression of VEGF and Ang-1 and the phosphorylation of Flk1 and Tie-1 were significantly decreased in DCM group as compared with those in the control group. However, those in the NRG-1 treatment group were significantly increased as compared with those in the DCM group. In vitro, NRG-1 treatment increased significantly the expression of VEGF and Ang-1 in human coronary artery smooth muscle cells.

Conclusions: NRG-1 can increase the myocardial angiogenesis of DCM, probably via the direct effects of NRG-1 and via the increasing expression of VEGF and Ang-1. These findings may contribute to developing a novel approach to reverse the impaired angiogenic responses in diabetes or coronary artery disease.

Keywords: Angiogenesis; Angiopoietin-1; Diabetic cardiomyopathy; Neuregulin-1; VEGF.

MeSH terms

  • Angiopoietin-1 / analysis
  • Angiopoietin-1 / metabolism
  • Animals
  • Cells, Cultured
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / pathology*
  • Diabetic Cardiomyopathies / complications
  • Diabetic Cardiomyopathies / metabolism
  • Diabetic Cardiomyopathies / pathology*
  • Male
  • Myocardium / metabolism
  • Myocardium / pathology*
  • Neovascularization, Pathologic / complications
  • Neovascularization, Pathologic / metabolism
  • Neovascularization, Pathologic / pathology*
  • Neuregulin-1 / analysis
  • Neuregulin-1 / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction
  • Vascular Endothelial Growth Factor A / analysis
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiopoietin-1
  • Neuregulin-1
  • Vascular Endothelial Growth Factor A